Clinical Trials | June 03, 2026
Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
The facility sets a new benchmark in respiratory diagnostics
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Collaboration brings Staart Prime, ChilRun and NikoMom products to Yoginii’s platform, strengthening its family-focused wellness ecosystem and supporting women through motherhood and family care
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The safety profile was described as manageable, though not without notable toxicities
Subscribe To Our Newsletter & Stay Updated
